title: Risks of chronic metabolic acidosis in patients with chronic kidney disease.
abstract: Risks of chronic metabolic acidosis in patients with chronic kidney disease. Metabolic acidosis is associated with chronic renal failure (CRF). Often, maintenance dialysis therapies are not able to reverse this condition. The major systemic consequences of chronic metabolic acidosis are increased protein catabolism, decreased protein synthesis, and a negative protein balance that improves after bicarbonate supplementation. Metabolic acidosis also induces insulin resistance and a decrease in the elevated serum leptin levels associated with CRF. These three factors may promote protein catabolism in maintenance dialysis patients. Available data suggest that metabolic acidosis is both catabolic and anti-anabolic. Several clinical studies have shown that correction of metabolic acidosis in maintenance dialysis patients is associated with modest improvements in nutritional status. Preliminary evidence indicates that metabolic acidosis may play a role in beta2-microglobulin accumulation, as well as the hypertriglyceridemia seen in renal failure. Interventional studies for metabolic acidosis have yielded inconsistent results in CRF and maintenance hemodialysis patients. In chronic peritoneal dialysis patients, the mitigation of acidemia appears more consistently to improve nutritional status and reduce hospitalizations. Large-scale, prospective, randomized interventional studies are needed to ascertain the potential benefits of correcting acidemia in maintenance hemodialysis patients. To avoid adverse events, an aggressive management approach is necessary to correct metabolic acidosis. Clinicians should attempt to adhere to the National Kidney Foundation Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines for maintenance dialysis patients. The guidelines recommend maintenance of serum bicarbonate levels at 22 mEq/L or greater.
authors.affiliation: Division of Nephrology and Hypertension, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, C-1 Annex, Torrance, CA90501-2052, USA. jkopple@labiomed.org
authors.forename: Joel D
authors.initials: JD
authors.lastname: Kopple
authors.forename: Kamyar
authors.initials: K
authors.lastname: Kalantar-Zadeh
authors.forename: Rajnish
authors.initials: R
authors.lastname: Mehrotra
mesh_terms: D000138:Acidosis / Q000209:etiology* / Q000378:metabolism / Q000503:physiopathology*; D000597:Amino Acids, Branched-Chain / Q000378:metabolism; D000818:Animals; D049454:Firefly Luciferin; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006962:Hyperparathyroidism, Secondary / Q000209:etiology / Q000503:physiopathology; D007333:Insulin Resistance; D007676:Kidney Failure, Chronic / Q000150:complications*; D020738:Leptin / Q000097:blood; D008156:Luciferases; D009752:Nutritional Status; D051381:Rats
chemical_list: D000597:Amino Acids, Branched-Chain; C114946:Chrono-lume; D020738:Leptin; D049454:Firefly Luciferin; D008156:Luciferases; D006854:Hydrocortisone